

# Michalis Doumas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5874473/michalis-doumas-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

268 papers	4,940 citations	37 h-index	63 g-index
321 ext. papers	6,169 ext. citations	4.6 avg, IF	5.76 L-index

#	Paper	IF	Citations
268	Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery Disease.. <i>American Journal of Cardiology</i> , <b>2022</b> ,	3	
267	Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.. <i>American Journal of Cardiology</i> , <b>2022</b> ,	3	0
266	Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. <i>European Journal of Heart Failure</i> , <b>2022</b> ,	12.3	1
265	Digital Biomarkers for Supporting Transitional Care Decisions: Protocol for a Transnational Feasibility Study.. <i>JMIR Research Protocols</i> , <b>2022</b> , 11, e34573	2	0
264	A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. <i>Angiology</i> , <b>2022</b> , 73, 87	2.1	8
263	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.. <i>Endocrine</i> , <b>2022</b> , 1	4	0
262	"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" comment.. <i>Internal and Emergency Medicine</i> , <b>2022</b> ,	3.7	
261	Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices.. <i>American Journal of Cardiology</i> , <b>2022</b> ,	3	
260	Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.. <i>American Journal of Cardiology</i> , <b>2022</b> ,	3	0
259	Impact of Primary Aldosteronism in Resistant Hypertension.. <i>Current Hypertension Reports</i> , <b>2022</b> , 1	4.7	0
258	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease.. <i>American Journal of Cardiology</i> , <b>2022</b> ,	3	0
257	Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	1
256	Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2021</b> , 106257	2.8	0
255	Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.. <i>American Journal of Cardiology</i> , <b>2021</b> ,	3	1
254	Colchicine for the prevention of COVID-19 "hard" outcomes: All that glitters is not gold. <i>European Journal of Internal Medicine</i> , <b>2021</b> ,	3.9	
253	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. <i>Journal of Human Hypertension</i> , <b>2021</b> ,	2.6	3
252	Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , <b>2021</b> ,	3	1

251	Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?. <i>International Journal of Cardiology</i> , <b>2021</b> ,	3.2	
250	Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders. <i>American Journal of Cardiology</i> , <b>2021</b> , 161, 120-122	3	
249	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. <i>American Journal of Cardiology</i> , <b>2021</b> , 161, 118-120	3	1
248	Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?. <i>Reumatologia</i> , <b>2021</b> , 59, 423-424	1.7	
247	Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?. <i>Kardiologia Polska</i> , <b>2021</b> , 79, 1048-1049	0.9	
246	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. <i>International Journal of Cardiology</i> , <b>2021</b> , 345, 119-124	3.2	2
245	Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. <i>World Journal of Cardiology</i> , <b>2021</b> , 13, 585-592	2.1	2
244	Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2021</b> ,	3	
243	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 301-312	3.3	2
242	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 323-342	3.3	8
241	Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1696-1700	6.7	1
240	Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?. <i>Kardiologia Polska</i> , <b>2021</b> , 79, 360	0.9	
239	Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 1289-1297	3.3	4
238	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. <i>Journal of Human Hypertension</i> , <b>2021</b> , 35, 825-827	2.6	2
237	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	6
236	Joint ESH excellence centers' National meeting on renal sympathetic denervation: A Greek experts' survey. <i>Hellenic Journal of Cardiology</i> , <b>2021</b> , 62, 355-358	2.1	1
235	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved. <i>Hypertension</i> , <b>2021</b> , 77, 1442-1455	8.5	4
234	Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?. <i>International Journal of Cardiology</i> , <b>2021</b> , 330, 228	3.2	0

233	Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 87, 100-101	3.9	1
232	Opportunistic screening for hypertension in the general population in Greece: International Society of Hypertension May Measurement Month 2019. <i>European Heart Journal Supplements</i> , <b>2021</b> , 23, B66-B69	1.5	0
231	Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?. <i>American Heart Journal</i> , <b>2021</b> , 236, 104-105	4.9	0
230	Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?. <i>Endocrinologia, Diabetes Y Nutrición</i> , <b>2021</b> ,	1.3	
229	Exercise blood pressure, cardiorespiratory fitness and mortality risk. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 67, 11-17	8.5	3
228	Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?. <i>Kidney Medicine</i> , <b>2021</b> , 3, 674-675	2.8	1
227	Female Sexual Dysfunction: A Problem Hidden in the Shadows. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 3762-3774	3.3	
226	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)-clinical phenotypes and their predictors based on a cohort of 1000 patients. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 950-959	9.9	16
225	Letter to the Editor: Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. <i>Hepatology</i> , <b>2021</b> , 73, 866	11.2	0
224	Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?. <i>International Journal of Cardiology</i> , <b>2021</b> , 323, 259	3.2	0
223	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. <i>Hypertension Research</i> , <b>2021</b> , 44, 179-187	4.7	8
222	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. <i>Microcirculation</i> , <b>2021</b> , 28, e12665	2.9	5
221	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. <i>American Journal of Cardiology</i> , <b>2021</b> , 138, 116-118	3	0
220	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest. <i>American Journal of Cardiology</i> , <b>2021</b> , 139, 134-136	3	0
219	Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials. <i>American Journal of Cardiology</i> , <b>2021</b> , 139, 139-141	3	3
218	Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1063-1065	6.7	2
217	Meta-Analysis Assessing the Effects of Allopurinol on Left Ventricular Mass and Other Indices of Left Ventricular Remodeling as Evaluated by Cardiac Magnetic Resonance Imaging. <i>American Journal of Cardiology</i> , <b>2021</b> , 138, 129-132	3	1
216	Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. <i>Acta Diabetologica</i> , <b>2021</b> , 58, 125-126	3.9	

215	Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis. <i>Indian Heart Journal</i> , <b>2021</b> , 73, 132-134	1.6	1
214	The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes. <i>JAMA Surgery</i> , <b>2021</b> , 156, 204	5.4	
213	The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis. <i>Blood Pressure Monitoring</i> , <b>2021</b> , 26, 284-287	1.3	2
212	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 4957-4968	3.9	3
211	Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 1	5.1	2
210	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 4671-4674	3.9	6
209	Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. <i>Endocrinology and Metabolism</i> , <b>2021</b> , 36, 904-908	3.5	5
208	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 2537-2544	3.3	
207	Torsemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 2714-2721	3.3	0
206	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1752-1760	50.5	93
205	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 572-581	3.3	6
204	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. <i>American Journal of Cardiology</i> , <b>2021</b> , 159, 143-146	3	2
203	Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation. <i>American Journal of Cardiology</i> , <b>2021</b> , 157, 150-152	3	
202	Impact of renal sympathetic denervation on cardiac magnetic resonance-derived cardiac indices in hypertensive patients - A meta-analysis. <i>Journal of Cardiology</i> , <b>2021</b> , 78, 314-321	3	0
201	"Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?". <i>European Journal of Internal Medicine</i> , <b>2021</b> ,	3.9	
200	Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 460-461	2.2	
199	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 77, 153-155	3.9	4
198	Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1220-1234	1.9	9

197	Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodium-glucose cotransporter-2 inhibitors?. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 343	1.9	1
196	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 562-571	2.3	14
195	Treatment strategies for hypertension in patients with type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1241-1252	4	5
194	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 572-584	2.3	17
193	Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?. <i>Acta Diabetologica</i> , <b>2020</b> , 57, 905-906	3.9	
192	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 172-181	3.3	24
191	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 125-138	3.3	3
190	Recent advances in understanding and managing resistant/refractory hypertension. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	3
189	Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 582-583	6.9	0
188	Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 922	1.9	
187	Dysmetabolic Iron Overload in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 1019-1024	3.3	12
186	Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. <i>Current Diabetes Reviews</i> , <b>2020</b> , 16, 313-326	2.7	16
185	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 887-893	3	2
184	Time to assess the effects of sodium-glucose co-transporter-2 inhibitors on the forgotten right ventricle?. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 337-338	3.7	2
183	Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 239-240	3.3	1
182	Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 3003-3005	3.6	5
181	Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2020</b> , 137, 130-132	3	1
180	Erectile dysfunction and adherence to antihypertensive therapy: Focus on $\beta$ -blockers. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 81, 1-6	3.9	6

179	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. <i>American Journal of Cardiology</i> , <b>2020</b> , 137, 133-135	3	1
178	Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , <b>2020</b> , 134, 149-152	3	2
177	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. <i>Journal of Human Hypertension</i> , <b>2020</b> , 34, 764-767	2.6	16
176	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non-diabetic CKD. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 2239-2249	2.3	3
175	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1929-1936	1.9	25
174	Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-11	2.7	15
173	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. <i>Current Hypertension Reports</i> , <b>2020</b> , 22, 90	4.7	22
172	Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 2389-2390	2.3	1
171	Primary Aldosteronism: Novel Insights. <i>Current Hypertension Reviews</i> , <b>2020</b> , 16, 19-23	2.3	3
170	Hypertension in Metabolic Syndrome: Novel Insights. <i>Current Hypertension Reviews</i> , <b>2020</b> , 16, 12-18	2.3	14
169	Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2020</b> , 14, 347	8.9	1
168	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. <i>Journal of Sexual Medicine</i> , <b>2019</b> , 16, 1199-1211	1.1	4
167	Physical Activity, Fitness, and Sexual Dysfunction <b>2019</b> , 373-387		
166	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 241-251	4.1	3
165	Now That Renal Denervation Works, How Do We Proceed?. <i>Circulation Research</i> , <b>2019</b> , 124, 693-695	15.7	11
164	Insomnia and hypertension: A misty landscape. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 835-837	2.3	2
163	Orthostatic hypertension: From pathophysiology to clinical applications and therapeutic considerations. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 426-433	2.3	23
162	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 425-428	3.3	4

161	Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 1135-1143	2.3	6
160	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 69, 1-7	3.9	2
159	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 1578-1579	2.3	0
158	Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus ( 2019:43:711-7). <i>Diabetes and Metabolism Journal</i> , <b>2019</b> , 43, 906-908	5	
157	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 331-332	6.9	
156	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. <i>Polish Archives of Internal Medicine</i> , <b>2019</b> , 129, 648-649	1.9	
155	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. <i>International Journal of Cardiology: Hypertension</i> , <b>2019</b> , 3, 100022	1.6	
154	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 156, 107927	7.4	10
153	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease A Tribute to Edward D. Freis <b>2019</b> , 75-88		
152	Metabolic syndrome: joint diagnostic criteria and links with comorbidities. <i>Hormones</i> , <b>2019</b> , 18, 107-108	3.1	
151	Prehypertension, the Risk of Hypertension and Events. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2019</b> , 37-55	0.1	
150	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 589-591	2.3	1
149	Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 701	1.9	2
148	Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 255-257	2.3	3
147	Diabetes and lipid metabolism. <i>Hormones</i> , <b>2018</b> , 17, 61-67	3.1	81
146	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 634-636	2.3	2
145	The potential role of statins in treating liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 331-339	4.2	10
144	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 469-471	2.3	2

143	Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 65-68	2.3	8
142	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 942-948	2.3	5
141	Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score. <i>American Journal of Hypertension</i> , <b>2018</b> , 31, 1197-1204	2.3	9
140	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , <b>2018</b> , 72, 641-649	8.5	54
139	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 1879-1886	3.3	11
138	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 4587-4592	3.3	18
137	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 5508-5516	3.3	4
136	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 130-142	3.3	36
135	The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 254-268	3.3	8
134	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 246-253	3.3	49
133	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 276-288	3.3	4
132	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 393-400	3.3	7
131	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. <i>Current Clinical Pharmacology</i> , <b>2018</b> , 13, 261-272	2.5	10
130	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 3638-3646	3.3	7
129	Antihypertensive drug treatment: the real-life challenge. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 115-117	1.3	1
128	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , <b>2018</b> , 12, 29-40	0.7	15
127	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2018</b> , 18, 120-126	1.1	2
126	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 71, 17-32	12.7	152

125	Left ventricular hypertrophy in athletes and hypertensive patients. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 413-417	2.3	29
124	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 249-253	5.5	30
123	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. <i>Journal of Hypertension</i> , <b>2017</b> , 35, 1750-1757	1.9	8
122	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2017</b> , 19, 39	2.1	5
121	Hematocrit and Stroke: A Forgotten and Neglected Link?. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 591-598	5.3	8
120	Blood pressure and cardiovascular outcomes: a closer look. <i>Lancet, The</i> , <b>2017</b> , 389, 1295-1296	4.0	1
119	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. <i>American Journal of Nephrology</i> , <b>2017</b> , 45, 136-145	4.6	10
118	Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 1336-1338	2.3	3
117	Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension. <i>Current Vascular Pharmacology</i> , <b>2017</b> , 16, 10-14	3.3	6
116	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. <i>Current Vascular Pharmacology</i> , <b>2017</b> , 16, 66-69	3.3	5
115	The effect of SGLT2 inhibitors on cardiovascular events and renal function. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1251-1261	3.8	9
114	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 1465.e27-1465.e39	2.4	10
113	Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1568-1571	3	7
112	Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1393	11.5	0
111	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 798-800	2.3	6
110	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. <i>Diabetes Care</i> , <b>2017</b> ,	14.6	53
109	Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	12
108	Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?. <i>Current Vascular Pharmacology</i> , <b>2017</b> , 16, 30-43	3.3	5

107	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 1510-1521	3.3	12
106	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 1477-1483	3.3	5
105	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 1540-1550	3.3	12
104	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. <i>Open Hypertension Journal</i> , <b>2017</b> , 9, 1-5	0.8	
103	Primary Aldosteronism: A Field on the Move. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2016</b> , 29-55	0.1	1
102	Renal Sympathetic Denervation: Hibernation or Resurrection?. <i>Cardiology</i> , <b>2016</b> , 135, 87-97	1.6	5
101	Depression in hypertensive patients: the role of comorbidities. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 1441	1.9	1
100	PATHWAY-2: spironolactone for resistant hypertension. <i>Lancet, The</i> , <b>2016</b> , 387, 1371-1372	4.0	
99	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 662	2.3	4
98	Discontinuation of Antihypertensive Treatment in Elderly Patients and Cognitive Function. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 409	11.5	
97	Lipids, Statins and Heart Failure: An Update. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 4796-4806	3.3	15
96	Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol. <i>Journal of Hypertension: Open Access</i> , <b>2016</b> , 05,		5
95	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. <i>American Journal of Nephrology</i> , <b>2016</b> , 43, 271-80	4.6	28
94	Selecting Optimum Antihypertensive Therapy <b>2016</b> , 217-247		
93	Renal Denervation: A Historical Perspective. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2016</b> , 201-213	0.1	
92	Approach to Erectile Dysfunction in Patients with Hypertension and Coronary Artery Disease <b>2016</b> , 309-327		1
91	Fitness: The "Secret" of Vascular Youth. <i>Journal of Clinical Hypertension</i> , <b>2016</b> , 18, 290-1	2.3	
90	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. <i>Clinical Lipidology</i> , <b>2016</b> , 11, 2-5		3

89	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. <i>Kidney International</i> , <b>2015</b> , 87, 649-59	9.9	124
88	Exaggerated Blood Pressure Response to Exercise: Will It Ever Be Ready for Prime Time?. <i>Journal of Clinical Hypertension</i> , <b>2015</b> , 17, 845-7	2.3	1
87	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 6820-34	5.6	91
86	Erectile dysfunction in chronic kidney disease: From pathophysiology to management. <i>World Journal of Nephrology</i> , <b>2015</b> , 4, 379-87	3.6	25
85	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 7860-8	5.6	97
84	Screening for Primary Aldosteronism: Whom and How?. <i>Journal of Clinical Hypertension</i> , <b>2015</b> , 17, 547-8	2.3	6
83	Hyperuricemia as a risk factor for cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 19-20	2.5	18
82	Recent advances in the management of resistant hypertension. <i>F1000prime Reports</i> , <b>2015</b> , 7, 03		2
81	PDE-5 inhibitors: clinical points. <i>Current Drug Targets</i> , <b>2015</b> , 16, 420-6	3	17
80	Sympathetic Renal Denervation Using the EnligHTN Multi-electrode Ablation System: The St Jude Experience <b>2015</b> , 69-79		
79	Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom). <i>Circulation Research</i> , <b>2014</b> , 115, 211-4	15.7	39
78	Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker. <i>American Journal of Hypertension</i> , <b>2014</b> , 27, 571-8	2.3	12
77	Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. <i>Circulation</i> , <b>2014</b> , 129, 1440-51	16.7	40
76	Exercise capacity and all-cause mortality in male veterans with hypertension aged ≥70 years. <i>Hypertension</i> , <b>2014</b> , 64, 30-5	8.5	39
75	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 415-22	1.9	59
74	Macro and microcirculation damage and incident hypertension: predictors of progression?. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 1154	1.9	6
73	Renal and cardiac effects of renal sympathetic denervation and carotid baroreceptor stimulation. <i>Current Vascular Pharmacology</i> , <b>2014</b> , 12, 55-62	3.3	10
72	Non-interventional management of resistant hypertension. <i>World Journal of Cardiology</i> , <b>2014</b> , 6, 1080-90	90.1	4

71	Carotid baroreceptor stimulation: a promising approach for the management of resistant hypertension and heart failure. <i>Current Vascular Pharmacology</i> , <b>2014</b> , 12, 30-7	3.3	10
70	Management of erectile dysfunction in hypertension: Tips and tricks. <i>World Journal of Cardiology</i> , <b>2014</b> , 6, 908-15	2.1	36
69	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. <i>Expert Review of Cardiovascular Therapy</i> , <b>2014</b> , 12, 295-6	2.5	1
68	Renal nerve ablation for resistant hypertension: the dust has not yet settled. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 399-400	2.3	3
67	Renal denervation: transition from pathophysiology to clinical practice. <i>Angiology</i> , <b>2014</b> , 65, 760-8	2.1	3
66	Antihypertensive therapy after acute ischemic stroke. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 2333-4	27.4	1
65	Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. <i>American Journal of Hypertension</i> , <b>2014</b> , 27, 422-30	2.3	19
64	Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 6339-49	3.3	14
63	Macro and microcirculation damage and incident hypertension. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 1154	1.9	2
62	Gender differences in hypertension: myths and reality. <i>Current Hypertension Reports</i> , <b>2013</b> , 15, 321-30	4.7	86
61	The impact of frequently encountered cardiovascular risk factors on sexual dysfunction in rheumatic disorders. <i>Andrology</i> , <b>2013</b> , 1, 556-62	4.2	10
60	Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. <i>Lancet, The</i> , <b>2013</b> , 381, 394-9	40	130
59	Statin and exercise prescription - AuthorsReply. <i>Lancet, The</i> , <b>2013</b> , 381, 1622-3	40	
58	Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 1263-74	2.5	60
57	Heart rate at rest, exercise capacity, and mortality risk in veterans. <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 1605-9	3	13
56	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 2109-17; discussion 2117	1.9	14
55	Divergent retinal vascular abnormalities in normotensive persons and patients with never-treated, masked, white coat hypertension. <i>American Journal of Hypertension</i> , <b>2013</b> , 26, 318-25	2.3	38
54	Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations. <i>Hypertension</i> , <b>2013</b> , 62, e21	8.5	

53	Platelet activation during exercise is not attenuated by inhibition of the renin-angiotensin system: the role of physical activity. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 2103	1.9	1
52	Effects of hypertension and antihypertensive therapy on sexual function in the elderly: the jury is still out. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 1917-8	1.9	3
51	Exercise capacity and progression from prehypertension to hypertension. <i>Hypertension</i> , <b>2012</b> , 60, 333-8	8.5	83
50	Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. <i>Current Hypertension Reports</i> , <b>2012</b> , 14, 238-46	4.7	21
49	Antihypertensive treatment and sexual dysfunction. <i>Current Hypertension Reports</i> , <b>2012</b> , 14, 285-92	4.7	65
48	Surgical management of primary aldosteronism. not everything that shines is gold. <i>Clinical and Experimental Hypertension</i> , <b>2012</b> , 34, 53-6	2.2	3
47	Leiomyosarcoma of renal vein, initially resembling pheochromocytoma. <i>Clinical and Experimental Hypertension</i> , <b>2012</b> , 34, 429-31	2.2	5
46	Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. <i>American Journal of Hypertension</i> , <b>2012</b> , 25, 444-50	2.3	31
45	Letter by Triantafyllou et al regarding article, "Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study". <i>Circulation</i> , <b>2012</b> , 126, e12; author reply e14	16.7	2
44	Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. <i>Journal of Clinical Rheumatology</i> , <b>2012</b> , 18, 422-30	1.1	47
43	BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 1021-7	14.6	77
42	Heart rate recovery, exercise capacity, and mortality risk in male veterans. <i>European Journal of Preventive Cardiology</i> , <b>2012</b> , 19, 177-84	3.9	21
41	Management of erectile dysfunction: do not forget hypertension. <i>Archives of Internal Medicine</i> , <b>2012</b> , 172, 597-8; discussion 598		4
40	Effects of antihypertensive therapy on female sexual dysfunction: clinically meaningful?. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 1263-4; author reply 1264-5	1.9	1
39	Sexual Function in Untreated and Treated Hypertension <b>2012</b> , 389-398		
38	Carotid baroreceptor stimulation for the treatment of resistant hypertension. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 964394	2.4	19
37	Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 196518	2.4	22
36	Common secondary causes of resistant hypertension and rational for treatment. <i>International Journal of Hypertension</i> , <b>2011</b> , 2011, 236239	2.4	49

35	Renal sympathetic denervation in hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2011</b> , 20, 647-53	3.5	22
34	Hypertension and sexual dysfunction: time to act. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 403-7	1.9	50
33	Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3586-97		16
32	The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. <i>Expert Opinion on Therapeutic Targets</i> , <b>2011</b> , 15, 75-89	6.4	24
31	Renal sympathetic denervation: renal function concerns. <i>Hypertension</i> , <b>2011</b> , 58, e19; author reply e20	8.5	24
30	Benefits from treatment and control of patients with resistant hypertension. <i>International Journal of Hypertension</i> , <b>2010</b> , 2011, 318549	2.4	12
29	Exercise capacity and mortality in older men: a 20-year follow-up study. <i>Circulation</i> , <b>2010</b> , 122, 790-7	16.7	230
28	Renal sympathetic denervation: the jury is still out. <i>Lancet, The</i> , <b>2010</b> , 376, 1878-80	4.0	39
27	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. <i>Journal of Hypertension</i> , <b>2010</b> , 28, 2299-308	1.9	37
26	Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. <i>Blood</i> , <b>2010</b> , 116, 631-9	2.2	103
25	Renal sympathetic denervation and systemic hypertension. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 570-6	3	61
24	Exercise capacity and mortality in hypertensive men with and without additional risk factors. <i>Hypertension</i> , <b>2009</b> , 53, 494-9	8.5	87
23	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. <i>Blood Pressure</i> , <b>2009</b> , 18, 261-7	1.7	33
22	Exercise capacity and all-cause mortality in prehypertensive men. <i>American Journal of Hypertension</i> , <b>2009</b> , 22, 735-41	2.3	36
21	Telmisartan for prevention of cardiovascular events. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 302; author reply 303	59.2	2
20	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. <i>Blood Pressure</i> , <b>2009</b> , 18, 261-267	1.7	2
19	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 955-66	4	3
18	Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. <i>Expert Opinion on Therapeutic Targets</i> , <b>2009</b> , 13, 413-25	6.4	26

17	Interventional management of resistant hypertension. <i>Lancet, The</i> , <b>2009</b> , 373, 1228-30	4.0	24
16	The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. <i>BMC Cardiovascular Disorders</i> , <b>2008</b> , 8, 11	2.3	26
15	Intracerebral hemorrhage as the presenting feature of concurrent pheochromocytoma and paragangliomas. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 941-4	2.3	3
14	Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. <i>Lancet, The</i> , <b>2008</b> , 371, 1921-6	4.0	364
13	Pheochromocytoma: ???The Great Mimic??? <b>2008</b> , 18, 121-123		
12	Sexual dysfunction: the prima ballerina of hypertension-related quality-of-life complications. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 2074-84	1.9	91
11	A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. <i>Journal of Immunology</i> , <b>2006</b> , 177, 4794-802	5.3	344
10	Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). <i>Angiology</i> , <b>2006</b> , 57, 313-20	2.1	10
9	Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. <i>Journal of Andrology</i> , <b>2006</b> , 27, 469-77		92
8	The effect of antihypertensive drugs on erectile function: a proposed management algorithm. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 359-64	2.3	63
7	Sexual dysfunction in essential hypertension: myth or reality?. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 269-74	2.3	29
6	Female sexual dysfunction in essential hypertension: a common problem being uncovered. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 2387-92	1.9	107
5	Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. <i>Asian Journal of Andrology</i> , <b>2006</b> , 8, 177-82	2.8	75
4	Sibutramine use associated with reversible hepatotoxicity. <i>Annals of Internal Medicine</i> , <b>2005</b> , 143, 763-4	8	9
3	Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 682-9	2.3	10
2	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. <i>Journal of Diabetes and Metabolic Disorders</i> , 1	2.5	
1	Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor		4